A Class II recall of Victoza (liraglutide) was initiated on March 22, 2021, according to FDA recall data. The recall, identified as D-0622-2021, was issued by Novo Nordisk Inc, the manufacturer of the product.
The reason given for the recall is temperature abuse. Product samples were reportedly stored at temperatures below 32 degrees Fahrenheit, which does not comply with required storage conditions. The FDA record states this could cause a lack of efficacy and damage to the cartridge and pen-injectors.
The affected product is described as Victoza (liraglutide) injection, 18 mg per 3 mL (6 mg/mL), distributed as a sample not for resale, Rx only. It was manufactured by Novo Nordisk A/S in Bagsvaerd, Denmark, and carries NDC numbers 0169-4060-90 for the pen and 0169-4060-99 for the kit.
The recall has since been listed with a status of terminated. The FDA classification of Class II indicates a specific regulatory categorization associated with this action, as recorded in the agency's recall database.
For general background on this compound, readers can consult the linked compound overview.</body_markdown> <parameter name="sources">["https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts"]